We established an inducible Kras G12D -driven lung adenocarcinoma in CCSP-rtTA/TetO-Cre/LSL-Kras G12D mice that enable pursuits of the cellular and molecular processes involved in Kras-induced tumorigenesis. To investigate the cellular origin of this cancer, we first report a strategy using fluorescence-activated cell sorting fractionation that could highly enrich bronchiolar Clara and alveolar type II cells, respectively. 
Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide (1) . Constitutive activation of the Kras oncogene was found in 20% to 40% of non-small-cell lung cancer, about 80% of which occurred at codon 12 (2) . Kras encodes a small GTPase that mediates a wide range of cellular functions, including proliferation, apoptosis, cytoskeletal remodeling, and differentiation (3) . There are primarily 2 major types of effector proteins: Rafs and phosphoinositide 3-kinase (PI3K). Raf serine/threonine kinases phosphorylate and activate mitogen-activated protein kinase kinases (MEK1/2), which in turn phosphorylate and activate extracellular signal-regulated kinases (ERK1/2; ref. 4 ). However, Sprouty-2 is an antagonist of Raf kinases that suppresses Ras-MEK-ERK signaling activation and tumorigenesis in Kras G12D -mediated lung cancer (5, 6) . In addition, the PI3K-Akt pathway is an essential cell survival pathway and cooperates with activated Raf to cause synergistic transforming activity (7) . Furthermore, Ras-dependent malignant transformation required the activation of Stat3 pathway (8) .
Different regions of resident stem/progenitor cells are responsible for lung postnatal growth, homeostasis, and repair of injured lungs, and contribute to local needs in times of tissue damage (9) . The Oct-3/4 positive lung stem/progenitor cells residing in the terminal bronchiolar region of neonatal lungs have been shown to be susceptible to SARS-CoV infection (10) . In addition, bronchioalveolar stem cells that reside in the bronchioalveolar junction of adult lungs express both Clara cell secretion proteins (CC10) and prosurfactant protein-C protein (proSPC), which are respective markers for bronchiolar Clara cells and alveolar type II cells (11) . Furthermore, other group have also identified rare population of lung epithelial stem/progenitor cells with the capacity for self-renewal and that give rise to airway and alveolar epithelial cell lineages in vitro (12) . Taking these results together, there is no direct evidence that these lung stem/progenitor cells are the sole inducer of bronchiogenic carcinomas of lungs. However, these studies may imply that tumorigenic cells or tumor-initiating cells of lung may be derived from bronchiolar Clara cells.
Identification of the cell origin of lung adenocarcinomas and defining the biochemical and biological changes that accompany their transformation are essential for the development of early detection and treatment. In this study, we first described the use of 3 surface markers, EpCAM, MHCII, and ICAM1, to enrich bronchiolar ciliated, Clara, and alveolar type II cells from normal lungs and Kras G12D -induced malignancies, investigated the cellular origin of lung adenocarcinomas, and determined the molecular processes that may be involved in Kras-induced tumorigenesis.
Materials and Methods

Mice
The conditional mutant mice are described in the Supplementary Materials and Methods.
Fluorescence-activated cell sorting analysis of total lung cells Single-cell suspension prepared from lung tissues of the mice are described in the Supplementary Materials and Methods. It was found that the total number of lung cells was approximately 1.3 Â 10 7 AE 0.2 Â 10 7 (mean AE SD, n ¼ 5) in the conditional mutant mice prior to Kras G12D activation. After Kras G12D activation for 12 weeks, the total number of lung cells recovered from mice was 7.6 Â 10 7 AE 0.7 Â 10 7 (mean AE SD, n ¼ 5).
Tumor engraftment analysis
Primary tumor cells were dissected from conditional mutant mice, which had received doxycycline administration for 12 weeks as described. Then, cell suspensions were pipetted into 200 mL of Dulbecco's modified Eagle's medium containing 20% fetal calf serum and injected into nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice intravenously. Hematoxylin and eosin (H&E)-stained sections of lung tumors of recipient mice were imaged on an Aperia microscope (Aperia Technologies) and stitched together using Snapshot software to measure the tumor number and size (diameter).
Percentages of Ki76
þ and pERK1/2 þ cells in secondary tumor areas were determined using MetaMorph software (Molecular Devices).
Immunofluorescence and immunohistochemical staining
The procedures of staining are described in the Supplementary Materials and Methods. 
Western blot and gene expression analysis
The procedures of Western blot and semiquantitative reverse transcriptase PCR (RT-PCR) are described in the Supplementary Materials and Methods.
Colony-formation assay and measurement of cytokines
The colony-formation assay are described in the Supplementary Materials and Methods.
Statistical analysis
Student t test was used to analyze the results of the experiments, and the P value was considered to be significant at less than 0.05. Data are expressed as the mean AE SE.
Results
Induced Kras
G12D activation with CCSP promoter activity CCSP-rtTA/TetO-Cre/LSL-Kras G12D conditional mutant mice were generated by cross-breeding CCSP-rtTA/TetO-Cre and LSL-Kras G12D mice (Fig. 1A) . In these mice, the expression of Cre recombinase is controlled by the tetracycline operator (tetO), which can be activated by the reverse tetracycline transactivator (rtTA) in the presence of doxycycline. The rtTA transgene is driven by the rat CCSP promoter, which is active in Clara cells in bronchioles and type II cells in alveoli (13) . In Fig.  1B , these mice displayed a shortened lifespan with a median survival of 15 weeks after Kras G12D activation, which was induced by the administration of doxycycline.
In contrast to mice prior to Kras G12D activation, 4 weeks of Kras G12D activation led to the development of epithelial hyperplasia in bronchioles and adenoma formation along alveoli (Fig. 1C) . After 12 weeks of Kras G12D activation, these lung lesions had subsequently progressed to adenocarcinomas in both the bronchiolar and alveolar regions (Fig. 1C) . However, the mutated Kras in our system was not expressed in tissues other than lungs after Kras G12D activation (Supplementary Fig.  S1A and B).
In mice prior to Kras G12D activation, the bronchiolar epithelium was positive for CC10, but negative for proSPC, whereas the alveolar epithelium was positive for proSPC, but negative for CC10 (Fig. 1D) . However, after 4 and 12 weeks of Kras G12D activation, bronchiolar tumor was also positive for CC10, but negative for proSPC, whereas alveolar tumor was negative for CC10 but showed intensive staining for proSPC (Fig. 1D) . Thus, this profile of expression in primary tumor located in both bronchiolar and alveolar regions was reminiscent of the findings in normal lung, reflecting the oncogenic activation of Kras G12D because of the CCSP promoter activity.
Furthermore, in mice prior to Kras G12D activation, the bronchiolar epithelium of lung tissue showed intensive staining for pan-cytokeratin (panCK), whereas alveolar epithelia were negative (Fig. 1D) . After 4 and 12 weeks of Kras G12D activation, epithelial hyperplasia or adenocarcinomas located in bronchiolar regions were positive for panCK staining; but, in contrast, only about half of the adenomas and adenocarcinoma cells in alveolar regions were focally positive for panCK staining (Fig. 1D) . These results implied that the initiating cells of lung tumor in the alveolar region might be derived from panCK þ bronchiolar epithelia.
Fluorescence-activated cell sorting fractionation of lung cells with lineage markers It was previously reported that the bronchiolar epithelium of normal lungs expresses either EpCAM or ICAM1, whereas the alveolar type II cell expresses MHCII and ICAM1 (12, 14, 15 Fig.   2A ). In addition, immunofluorescence staining confirmed that the EpCAM 
Tumorigenicity of different cell fractions of primary tumors
We also found that primary tumors could be serially engrafted into immunodeficient mice to generate secondary and tertiary tumors ( Supplementary Fig. S3A ). These secondary tumor cells were positive for ICAM1, but negative for FoxJ1 ( Supplementary Fig. S3B and C) and b-tubulin IV expression (data not shown). We then examined which fraction of the Kras G12D -induced lung adenocarcinoma in primary tumors behave as cancer stem-like cells to generate secondary tumors, with not only the self-proliferation abilities but also displaying diversities in tumor locations, as well as phenotypic expression.
To 3A and B ). In addition, the limiting dilution assay showed that a highly significant 6.6-fold enrichment for tumorigenic potential for EpCAM þ MHCII À cell fraction ( Fig. 3C ; Supplementary EpCAM þ MHCII þ cell fractions were counted on tissue sections (mean AE SD, Ã , P < 0.01, n ¼ 6, 2-tailed t test; the number of mice used was presented in Supplementary Table S1 Phenotypic diversity of EpCAM þ MHCII À -generated secondary tumors The primary tumors in the bronchiolar region were positive for panCK staining, although about half of the primary tumors in the alveolar region were only focally positive for panCK staining (Fig. 1D) . To test the hypothesis that panCK þ tumors in the alveolar region might have been derived from the bronchiolar cell origin, we first examined which cell fraction in the normal and the primary tumors express panCK þ tumors.
As shown in Supplementary Fig. S4 Fig. S4 ).
On the other hand, in the bronchiolar region, secondary tumors derived from the injection of the EpCAM þ MHCII À cell fraction were positive for panCK staining (Fig. 3E ) that was consistent with the findings from primary tumors in the bronchiolar region (Fig. 1D ). In addition, in the alveolar region, secondary tumors derived from the same cell fraction were also mostly positive for panCK; but also positive for proSPC staining (Fig. 3E) of Ki67 þ cells in Fig. 3F ). This finding was consistent with the observation of larger tumor nodules in secondary tumors derived from the EpCAM þ MHCII À cell fraction (Fig. 3A-C) .
The Kras signaling pathway
The downstream effectors of Kras signaling pathways, such as MEK1/2, ERK1/2, Akt, Stat3, and miR-21 were required for Kras-driven lung adenocarcinoma and crucial for tumor maintenance after the establishment of sizeable tumors (16) (17) (18) activation for 12 weeks. GAPDH and b-actin were used as internal controls (mean AE SD, Ã , P < 0.05, n ¼ 5, 2-tailed t test). B, Western blot of phosphorylated ERK1/2, total ERK1/2, and b-actin in each cell fraction from mice prior to and after Kras G12D activation for 12 weeks (mean AE SD, Ã , P < 0.05, n ¼ 5, 2-tailed t test). C, immunohistochemical staining of lung tissue sections for phosphorylated ERK1/2 and total ERK1/2 expressions in bronchiolar and alveolar regions. D, RT-PCR and Western blot analyses of Sprouty-2 expressions (mean AE SD, Ã , P < 0.01, n ¼ 5, 2-tailed t test). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
It was also found that phosphorylated ERK1/2 þ cells had obviously increased in primary bronchiolar tumors of the lungs after 12 weeks of Kras G12D activation, whereas there were a few phosphorylated ERK1/2 þ cells scattered within the alveolar region (Fig. 4C) . These findings were consistent with the staining pattern of phosphorylated ERK1/2 in EpCAM þ MHCII À cells (Fig. 4B) . It was further found that secondary tumors derived from the EpCAM þ MHCII À cell fraction more highly expressed phosphorylated ERK1/2 compared with secondary tumors originating from the EpCAM
in Fig. 3F ), indicating that the Kras signaling pathway were highly activated in the EpCAM þ MHCII À cell fraction.
On the other hand, the expression of Sprouty-2 was low in both the EpCAM
of mice prior to Kras G12D activation (Fig. 4D) . However, after 12 weeks of Kras G12D activation, the expression levels of Sprouty-2 RNA and protein in the EpCAM þ MHCII þ cell fraction, respectively, increased by 7-and 15-fold compared with those in the EpCAM þ MHCII À cell fraction (Fig. 4D) Fig. 3A and B ).
To determine whether ERK1/2 activation was involved in colony formation of tumor cells, the MEK inhibitor PD98059, which inhibits the phosphorylation of ERK1/2, was added to the culture medium of the lower chamber. After treatment of cells with PD98059 for 8 to 10 days, the colony numbers of EpCAM On day 0, the culture medium in the lower chamber was treated with dimethyl sulfoxide (DMSO), and 5 and 10 mmol/L of a MEK inhibitor (PD98059). After 8 to 10 days of culture, the colony number was counted by inverted microscopy (mean AE SD, Ã , P < 0.05, n ¼ 5, 2-tailed t test). D, similarly, cells were seeded in transwells as in (C) and treated with DMSO and 10 mmol/L of MEK inhibitor (PD98059) in the lower chamber. After 2 days of culture, the conditioned medium in the lower chamber was collected, and cytokine production was assayed (mean AE SD, Ã , P < 0.05, n ¼ 3, 2-tailed t test).
Ciliated cell
Clara but 10 mmol/L of PD98059 significantly reduced colony formation by 9.8-fold (Fig. 5C ). It was noted that oncogenic Ras induced the secretion of the interleukin (IL)-6 and KC from a variety of cell types that mediate tumor growth and angiogenesis (19, 20) , implying that these two cytokines are regulated by the Ras-MEK-ERK pathway. To test this hypothesis, cultured medium in the lower chamber from EpCAM þ MHCII À cells was collected after treatment with 10 mmol/L of PD98059 for 2 days and then cytokine production was determined. The production of IL-6 and KC from EpCAM þ MHCII À cells was blocked by PD98059 (by 3.2-and 5.8-fold) compared with the control (Fig. 5D) , suggesting that the ERK signaling pathway was involved in IL-6 and KC secretion by EpCAM þ MHCII À cells.
Discussion
The bronchiolar adenocarcinomas and bronchoalveolar cell carcinomas of the peripheral airways are the most common types of lung cancer worldwide (21) . These tumors might arise from Clara cells present in bronchioles or type II cells in alveoli (22, 23) . However, the initiating cells in lung epithelium from which lung adenocarcinomas originate are poorly understood. Therefore, the identification of lung tumorigenic or tumorinitiating cells and their associated biomarkers or biosignatures will be useful for development of new detection methods and therapeutics for lung cancers. As illustrated in Fig. 6 In this study, the EpCAM antigen was combined with MHCII and ICAM1 antigens to characterize and purify these cells and tumors in different regions in respective cell fractions by fluorescence-activated cell sorting (FACS) fractionation. Therefore, the development of lung lesions and different types of cancer progression after oncogenic activation could be monitored. Thus, this model might provide an efficient tool to examine signaling profiles of bronchiolar and alveolar tumors and analyze potential differential sensitivities of bronchiolar and alveolar tumors to conventional drugs and specific inhibitors.
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